General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FLEUN
ADC Name
Anti-HER2 DVD-Fab-h38c2-K99C_MMAF
Synonyms
Anti-HER2 DVD-Fab-H38c2-K99C MMAF
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
0.9
Structure
Antibody Name
Anti-HER2 DVD-Fab-h38c2-K99C
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Monomethyl auristatin F
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Dibromomaleimide-PEG4
 Linker Info 
Conjugate Type
Dibromomaleimide selectively reacts with the engineered cysteine residue of h38C2_K99C DVD-Fab, Michael addition reaction.
Combination Type
Dibromomaleimide-PEG4-MMAF
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.33
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Effective Concentration (EC50) 
> 10
uM
MDA-MB-231 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.33 nM High HER2 expression (HER2+++)
Method Description
Breast cancer SK-BR-3 (HER2+) and MDA-MB-231 (HER2-) cells were seeded in 96-well tissue culture plates. The prepared ADCs and their corresponding unconjugated DVD-IgG1 were added to the cells at 10-fold serial dilution (0.001100 nM), followed by incubation at 37°C, 5% CO2 for 72 h. Cell viability was then measured using CellTiter 96 aqueous one solution (Promega) and plotted as a percentage of untreated cells.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) > 10.00 uM Negative HER2 expression (HER2-)
Method Description
Breast cancer SK-BR-3 (HER2+) and MDA-MB-231 (HER2-) cells were seeded in 96-well tissue culture plates. The prepared ADCs and their corresponding unconjugated DVD-IgG1 were added to the cells at 10-fold serial dilution (0.001100 nM), followed by incubation at 37°C, 5% CO2 for 72 h. Cell viability was then measured using CellTiter 96 aqueous one solution (Promega) and plotted as a percentage of untreated cells.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Bioconjug Chem. 2022 Jun 15;33(6):1192-1200.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.